Daewoong Pharmaceutical (Daewoong) said on Sept. 1 that its self-developed botulinum toxin Nabota received a marketing authorization from Malaysia's National Drug Administration on Aug. 30.
Local distribution and sales will be handled by Hyphens Pharma (Hyphens). Hyphens Pharma's parent company, Hyphens Group, is a Singapore Exchange-listed pharmaceutical and healthcare group specializing in the Southeast Asian market with subsidiaries in six ASEAN countries.
Daewoong and Hyphens will actively utilize social media campaigns and mobile advertising to communicate Nabota's strengths in the Malaysian market, which is characterized by an expanding young and middle class.
"Nabota, a global toxin representative, has been performing exceptionally well in big markets such as the U.S., Europe, Brazil, Thailand, Taiwan, and Turkey after ranking first in Korea in the first half of 2023," said Park Seong-soo, Vice President of Daewoong Pharmaceutical. "Daewoong will successfully establish itself in Malaysia and target the Muslim market of 2 billion people to grow Nabota into a global No. 1 toxin."
As of August 2023, Nabota is licensed in 66 countries worldwide, including the United States and Europe. The company plans to launch in Australia in 2024 and is in the process of licensing in China.
